According to epidemiological studies, the prevalence rate of cerebral vein thrombosis (CVT) is 10–12 per million in Iran and 4–7 per million in the world [
1,
2]. One or more sinuses and cerebral veins are blocked, reducing the blood flow of the brain and cerebrospinal fluid [
2]. CVT clinical manifestation depends on thrombosis location and includes: headache, seizure, focal neurological deficit, increasing intracranial pressure, loss of consciousness, vertigo, and vomiting [
1,
3,
4]. CVT increases in young adults, women of childbearing age, and children. Affected children are usually newborns. The age of patients with CVT ranges from newborn to 82 years old, but this condition occurs mainly in individuals between 30 and 41 years old [
3]. Although the mortality rate of CVT has been significantly reduced by improvements in treatment and diagnostic techniques, the mortality rate of severe CVT remains as high as 34.2%. Considering the risk factors can help to diagnose it. The incidence of infectious CVT was significantly reduced by the use of antibiotics, whereas the incidence of CVT associated with other factors, including trauma, Behcet’s disease, the perinatal period, use of oral contraceptives, neoplasms, nephrotic syndrome, coagulation factor, and other abnormalities, was higher. With the advent of new diagnostic techniques, such as computed tomographic venography (CTV) and magnetic resonance angiography (MRA), it has become easier to achieve an early diagnosis of CVT [
5]. Because of the comfortable use of oral contraceptive pills (OCPs), their daily use is increasing among women [
5]. OCPs are known as an effective contraception and are prescribed for the treatment of some diseases. Oral contraceptives seem to increase the risk of cerebral venous sinus thrombosis (CVST) owing to their estrogenic component because estrogens increase the levels of coagulation factors and decrease the levels of anticoagulant proteins such as antithrombin and proteins. According to several observational studies, females who consumed OCPs had a 5- to 22-fold-increased risk of CVT. Among the various types of combined hormonal contraceptives (CHCs), third-generation CHCs containing desogestrel or gestoden reportedly confer the highest risk for CVT [
6,
7]. Although the effect of OCP increases the risk of CVT, relatively high brain venous involvement is rare in short-duration consumption of OCPs.